Patient characteristics at study entry (n = 617)
. | Pre-ULR group, n = 315 . | Post-ULR group, n = 302 . | P . |
|---|---|---|---|
| Age, y, mean ± SD | 45 ± 15 | 47 ± 14 | .16‡ |
| Female, no. (%) | 147 (47) | 111 (37) | .016§ |
| Nulliparous/nontransfused (%)* | 144 (48) | 158 (53) | .27§ |
| Disease (%) | |||
| AML | 124 (39) | 135 (45) | |
| ALL | 37 (12) | 19 (6) | |
| CML | 31 (10) | 21 (7) | |
| MM | 28 (9) | 41 (14) | |
| MDS | 22 (7) | 19 (6) | |
| AA | 7 (2) | 2 (1) | |
| HD | 27 (9) | 15 (5) | |
| NHL | 32 (10) | 47 (16) | |
| GCT | 7 (2) | 3 (1) | |
| Treatment (%) | |||
| Chemotherapy/supportive care† | 116 (37) | 117 (39) | .68§ |
| SCT | 199 (63) | 185 (61) | |
| Allogeneic sibling | 75 (38) | 72 (39) | |
| Allogeneic VUD | 39 (19) | 32 (17) | |
| Autologous | 84 (42) | 80 (43) | |
| Syngeneic | 1 (1) | 1 (1) |
. | Pre-ULR group, n = 315 . | Post-ULR group, n = 302 . | P . |
|---|---|---|---|
| Age, y, mean ± SD | 45 ± 15 | 47 ± 14 | .16‡ |
| Female, no. (%) | 147 (47) | 111 (37) | .016§ |
| Nulliparous/nontransfused (%)* | 144 (48) | 158 (53) | .27§ |
| Disease (%) | |||
| AML | 124 (39) | 135 (45) | |
| ALL | 37 (12) | 19 (6) | |
| CML | 31 (10) | 21 (7) | |
| MM | 28 (9) | 41 (14) | |
| MDS | 22 (7) | 19 (6) | |
| AA | 7 (2) | 2 (1) | |
| HD | 27 (9) | 15 (5) | |
| NHL | 32 (10) | 47 (16) | |
| GCT | 7 (2) | 3 (1) | |
| Treatment (%) | |||
| Chemotherapy/supportive care† | 116 (37) | 117 (39) | .68§ |
| SCT | 199 (63) | 185 (61) | |
| Allogeneic sibling | 75 (38) | 72 (39) | |
| Allogeneic VUD | 39 (19) | 32 (17) | |
| Autologous | 84 (42) | 80 (43) | |
| Syngeneic | 1 (1) | 1 (1) |
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MM, multiple myeloma; MDS, myelodysplastic syndrome; AA, aplastic anemia; HD, Hodgkin disease; NHL, non-Hodgkin lymphoma; GCT, germ cell tumor; SCT, stem cell transplantation; and VUD, volunteer unrelated donor.
Nulliparous patients and no transfusion more than 2 weeks before study entry; data were not obtained in 22 patients (17 in the before group and 5 in the after group).
Patients receiving chemotherapy for AML (n = 181) or ALL (n = 31) or supportive care only for AA (n = 5) or MDS (n = 16).
T test.
Chi-square test.